Literature DB >> 7888678

Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes.

D Zhu1, D G Oscier, F K Stevenson.   

Abstract

Splenic lymphoma with villous lymphocytes (SLVL) is a recently defined subgroup of chronic B-cell lymphoproliferative diseases. The characteristic morphology of the tumor cells, together with phenotypic and cytogenetic findings, indicate that it is a distinct entity, but the nature of the cell or origin and its relationship to other low-grade lymphomas is unclear. For B-cell tumors, analysis of the variable region heavy chain (VH) genes used to encode the clonal Ig has shown marked differences between histologic categories, both in gene usage and extent of somatic mutation. An investigation of VH genes used in five typical cases of SLVL has shown somatic hypermutation from germline sequences in all cases, indicating that the cell of origin has been exposed to the hypermutation mechanism. However, no clonal heterogeneity was detectable, demonstrating that the tumor cell does not accumulate further mutations. These characteristics are similar to those found in mature postfollicular B cells, such as plasma cells. The distribution of mutations leading to replacement amino acids differed among the cases, with three of five cases showing clear evidence for antigen selection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7888678

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells.

Authors:  H K Müller-Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 2.  Somatic hypermutation and B-cell lymphoma.

Authors:  D Dunn-Walters; C Thiede; B Alpen; J Spencer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

3.  Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.

Authors:  E D Remstein; C D James; P J Kurtin
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

4.  Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma.

Authors:  Kostas Stamatopoulos; Chrysoula Belessi; Theodora Papadaki; Evangelia Kalagiakou; Niki Stavroyianni; Vassiliki Douka; Stavroula Afendaki; Riad Saloum; Aikaterini Parasi; Dimitra Anagnostou; Nikolaos Laoutaris; Athanasios Fassas; Achilles Anagnostopoulos
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

5.  Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations.

Authors:  Anne Tierens; Jan Delabie; Agnieszka Malecka; Junbai Wang; Alicja Gruszka-Westwood; Daniel Catovsky; Estella Matutes
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

6.  No V(H) somatic hypermutation was detected in B-cells of a patient with macroglobulinemia due to splenic marginal zone lymphoma.

Authors:  Tetsuaki Sekikawa; Shinobu Takahara; Takeshi Kawano; Shuji Nakada; Kiyoshi Ito; Satsuki Iwase; Hisashi Yamada; Masayuki Kobayashi; Junko Horiguchi-Yamada
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

Review 7.  Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes.

Authors:  Xavier Troussard; Edouard Cornet
Journal:  Curr Treat Options Oncol       Date:  2007-04

8.  Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.

Authors:  Veronica S Gil; Govind Bhagat; Louise Howell; Jiyuan Zhang; Chae H Kim; Sven Stengel; Francisco Vega; Arthur Zelent; Kevin Petrie
Journal:  Dis Model Mech       Date:  2016-10-28       Impact factor: 5.758

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.